Activated protein C resistance and @entity5337 mutation are independent risk factors for XXXX .

@entity1 @entity5337 @entity7131 @entity54821 @entity1211 @entity130
BACKGROUND: Resistance to activated @entity7131 due to the factor V @entity54821 (Leiden) mutation is the most common clotting abnormality in @entity1 with @entity1211 . OBJECTIVE: To evaluate the risk for @entity1211 associated with the @entity5337 mutation or with resistance to activated @entity7131 in the general population. DESIGN: Cross-sectional survey. SETTING: General community of Vicenza, Italy. @entity1 : A population-based sample of 15,109 white @entity1 18 to 65 years of age who were randomly selected from the census list. MEASUREMENTS: Sequential validated approach based on @entity1 ' reports and Doppler ultrasonography. Resistance to activated @entity7131 was investigated in all @entity1 ; 2134 @entity1 with resistance to activated @entity7131 were screened for the @entity5337 mutation. RESULTS: Carriers of the @entity5337 mutation had a relative risk of 3.3 (95% CI, 1.7 to 6.1) for @entity1211 before 65 years of age. The fraction of cases attributable to the @entity5337 mutation was 6.6%. By 65 years of age, 5.7% of carriers of the mutation had had @entity1211 , mostly after surgery. @entity1 with a reduced response to activated @entity7131 were at higher risk even if they did not carry the mutation (odds ratio, 1.7 [CI, 1.0 to 2.7]); the attributable risk for @entity1211 was 5.1%. CONCLUSIONS: The @entity5337 mutation and resistance to activated @entity7131 are important, independent risk factors for @entity1211 . Screening strategies for the @entity5337 mutation in @entity1 undergoing surgery or experiencing @entity130 cannot be recommended, but phenotypic evaluation of resistance to activated @entity7131 should be encouraged in @entity1 with @entity1211 .
